Table II.
Results of subgroup analysis of comparing AR CAG biallelic mean of cases and controls.
| Number of studies | WMD (95% CI) | Heterogeneity |
||
|---|---|---|---|---|
| P | I2 (%) | |||
| Overall | 12 | −0.06 (−0.29 to 0.16) | 0.06 | 41.9 |
| Subgroups | ||||
| Geographic location | ||||
| Europe | 6 | −0.20 (−0.54 to 0.13) | 0.19 | 32.9 |
| Asia | 3 | 0.072 (−0.20 to 0.34) | 0.70 | 0.0 |
| America | 2 | −0.35 (−0.74 to 0.04) | 0.60 | 0.0 |
| Oceaniaa | 1 | 0.66 (0.09–1.24) | — | — |
| Ethnicity | ||||
| Caucasian | 8 | −0.11 (−0.44 to 0.23) | 0.02 | 57.9 |
| Asian | 3 | 0.07 (−0.20 to 0.34) | 0.70 | 0.0 |
| Blacka | 1 | −0.13 (−1.03 to 0.77) | — | — |
| PCOS definition | ||||
| ESHRE/ASRM | 7 | −0.09 (−0.36 to 0.18) | 0.11 | 42.7 |
| NIH | 2 | −0.35 (−0.74 to 0.04) | 0.60 | 0.0 |
| Other | 3 | 0.26 (−0.32 to 0.84) | 0.20 | 38.4 |
| Sample size of cases | ||||
| ≥100 | 6 | 0.01 (−0.32 to 0.34) | 0.01 | 66.0 |
| <100 | 6 | −0.22 (−0.53 to 0.08) | 0.73 | 0.0 |
aOnly one study was in the subgroup so that P and I2 for heterogeneity could not be calculated.